Figure 1. Longitudinal incidence of new SARS-CoV-2 infections in the cohort of patients with hematological malignancy who received Evusheld versus the local community. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
| Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
| Journal website https://www.thejh.org |
Short Communication
Volume 11, Number 6, December 2022, pages 210-215
Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
Figure
Tables
| Hematological malignancy | Number of cases (%) | Median age (range) | Number of female | Number of receiving treatment |
|---|---|---|---|---|
| Chronic lymphocytic leukemia | 93 (46) | 73 (36 - 94) | 40 | 55 |
| Multiple myeloma | 36 (18) | 70 (54 - 91) | 17 | 35 |
| Follicular lymphoma | 17 (8) | 66 (56 - 85) | 11 | 14 |
| Waldenstrom macroglobulinemia | 16 (8) | 73 (43 - 93) | 7 | 16 |
| Diffuse large B-cell lymphoma | 15 (7) | 76 (53 - 88) | 7 | 14 |
| Marginal zone lymphoma | 6 (3) | 69 (59 - 70) | 4 | 6 |
| Mantle cell lymphoma | 5 (2) | 80 (62 - 86) | 0 | 5 |
| Acute myeloid leukemia | 4 (2) | 72 (67 - 82) | 0 | 4 |
| Large granular lymphocytic leukemia | 3 (1) | 71 (62 - 92) | 2 | 3 |
| Acute lymphocytic leukemia | 2 (1) | 61 (53 - 68) | 1 | 2 |
| Monoclonal gammopathy of unknown significance | 2 (1) | 78 (78) | 1 | 1 |
| B-cell prolymphocytic leukemia | 1 (0.5) | 70 (70) | 0 | 1 |
| Chronic myeloid leukemia | 1 (0.5) | 63 (63) | 1 | 1 |
| Hairy cell leukemia | 1 (0.5) | 62 (62) | 0 | 1 |
| Peripheral T-cell lymphoma | 1 (0.5) | 88 (88) | 0 | 1 |
| Chemotherapy medication | Frequency of use (% of total patients) |
|---|---|
| Rituximab | 89 (44) |
| Cyclophosphamide | 42 (21) |
| Ibrutinib | 40 (20) |
| Bendamustine | 39 (19) |
| Prednisone | 39 (19) |
| Lenalidomide | 32 (16) |
| Dexamethasone | 29 (14) |
| Vincristine | 25 (12) |
| Bortezomib | 24 (12) |
| Daratumumab | 22 (11) |
| Fludarabine | 20 (10) |
| Adriamycin | 17 (8) |
| Venetoclax | 15 (7) |
| Chlorambucil | 10 (5) |
| Acalabrutinib | 7 (3) |
| Methotrexate | 5 (2) |
| Pomalidomide | 5 (2) |
| Cytarabine | 4 (2) |
| Decitabine | 4 (2) |
| Doxorubicin | 4 (2) |
| Melphalan | 4 (2) |
| Daunorubicin | 3 (1) |
| Obinutuzumab | 3 (1) |
| 6-mercaptopurine | 2 (1) |
| Asparaginase | 2 (1) |
| Cladribine | 2 (1) |
| Elotuzumab | 2 (1) |
| Oxaliplatin | 2 (1) |
| Bosutinib | 1 (0.5) |
| Carfilzomib | 1 (0.5) |
| Cisplatin | 1 (0.5) |
| Dasatinib | 1 (0.5) |
| Docetaxel | 1 (0.5) |
| Epirubicin | 1 (0.5) |
| Fluorouracil | 1 (0.5) |
| Imexon | 1 (0.5) |
| Interferon alpha | 1 (0.5) |
| Ivosidenib | 1 (0.5) |
| Nelarabine | 1 (0.5) |
| Ofatumumab | 1 (0.5) |
| Pembrolizumab | 1 (0.5) |
| Pertuzumab | 1 (0.5) |
| Thalidomide | 1 (0.5) |